tert-butyl (3S)-3-fluoro-4-oxopiperidine-1-carboxylate | 1450879-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (3S)-3-fluoro-4-oxopiperidine-1-carboxylate
• 英文别名: tert-butyl (S)-3-fluoro-4-oxopiperidine-1-carboxylate；1-Boc-3S-fluoropiperidin-4-one
• CAS: 1450879-67-0
• 化学式: C₁₀H₁₆FNO₃
• 分子量: 217.24
• InChiKey: JZNWQLLPLOQGOI-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S)-3-fluoro-4-oxopiperidine-1-carboxylate 在 tetramethylammonium borohydride 作用下， 以 甲醇 为溶剂， 反应 4.25h， 以75%的产率得到(3S,4R)-3-氟-4-羟基哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  Enantioselective Synthesis of cis-3-Fluoropiperidin-4-ol, a Building Block for Medicinal Chemistry

  摘要：

  The first enantioselective route to both enantiomers of cis-1-Boc-3-fluoropiperidin-4-ol, a highly prized building block for medicinal chemistry, is reported. An enantioselective fluorination is employed, taking advantage of the methodology reported by MacMillan, which uses a modified cinchona alkaloid catalyst. In studying the fluorination reaction, we have shown that the catalyst can be replaced by commercially available primary amines, including α-methylbenzylamine, with similar levels of enantioselectivity. The piperidinols are readily crystallized to obtain enantiopure material.

  DOI：

  10.1021/jo401352z
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 (R)-α-methylbenzylamine monotrichloroacetic acid 、 sodium carbonate 、 N-氟代双苯磺酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以72%的产率得到tert-butyl (3S)-3-fluoro-4-oxopiperidine-1-carboxylate
  参考文献：
  名称：

  Enantioselective Synthesis of cis-3-Fluoropiperidin-4-ol, a Building Block for Medicinal Chemistry

  摘要：

  The first enantioselective route to both enantiomers of cis-1-Boc-3-fluoropiperidin-4-ol, a highly prized building block for medicinal chemistry, is reported. An enantioselective fluorination is employed, taking advantage of the methodology reported by MacMillan, which uses a modified cinchona alkaloid catalyst. In studying the fluorination reaction, we have shown that the catalyst can be replaced by commercially available primary amines, including α-methylbenzylamine, with similar levels of enantioselectivity. The piperidinols are readily crystallized to obtain enantiopure material.

  DOI：

  10.1021/jo401352z

文献信息

• [EN] THIADIAZOLE IRAK4 INHIBITORS<br/>[FR] INHIBITEURS DE THIADIAZOLE IRAK4
  申请人：GILEAD SCIENCES INC

  公开号：WO2020036986A1

  公开（公告）日：2020-02-20

  A compound of Formula (I): (I) pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

  公开了化合物Formula (I)的复合物：(I)的药用盐，其氘代物，其组合物，以及使用其化合物治疗疾病的方法。
• [EN] KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE ET LEURS UTILISATIONS
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2018213632A1

  公开（公告）日：2018-11-22

  The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

  本公开涉及化合物和组合物，中间体，它们的制备过程，以及它们作为激酶抑制剂的用途。
• Thiadiazole IRAK4 compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11046686B2

  公开（公告）日：2021-06-29

  A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

  式 (I) 的化合物： 公开了其药学上可接受的盐、其氚代类似物、其组合物以及使用其化合物治疗疾病的方法。
• KINASE INHIBITORS AND USES THEREOF
  申请人：Denali Therapeutics Inc.

  公开号：EP3624797A1

  公开（公告）日：2020-03-25
• [EN] TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES TRICYCLIQUES, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：[en]DANATLAS PHARMACEUTICALS CO., LTD.

  公开号：WO2023208092A1

  公开（公告）日：2023-11-02

  The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.